1. Davies N.(2018).The future of biologics.Pharm Lettwww.thepharmaletter.com/article/the‐future‐of‐biologics(accessed 20 June 2020).
2. The
US
Biosimilar Market: Stunted Growth and Possible Reforms
3. Identifying key benefits in European off‐patent biologics and biosimilar markets: it is not only about price!;Dutta B.;BioDrugs,2019
4. Human Insulin from Recombinant DNA Technology
5. WHO(2009).Health Organization expert committee on biological standardization. Guidelines on evaluation of similar biotherapeutic products (SBPs).https://www.who.int/biologicals/publications/trs/areas/biological_therapeutics/TRS_977_Annex_2.pdf?ua=1(accessed 17 February 2020).